Annovis BioFRA:07X -4.06%38 Quick Ratio is 1.27 as of Mar. 2026, which is 73% below its 10-year median of 4.68. GuruFocus rates FRA:07X with a GF Score™ of 38/100. The stock has 1 warning sign investors should review. Among 1,412 Biotechnology companies, Annovis Bio ranks worse than 76.63% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Annovis Bio's quick ratio for the quarter that ended in Mar. 2026 was 1.27.
Annovis Bio has a quick ratio of 1.27. It generally indicates good short-term financial strength.
The historical rank and industry rank for Annovis Bio's Quick Ratio or its related term are showing as below:
FRA:07X'
s Quick Ratio Range Over the Past 10 Years
Min: 0.09 Med: 4.68 Max: 55.99
Current: 1.27
During the past 9 years, Annovis Bio's highest Quick Ratio was 55.99. The lowest was 0.09. And the median was 4.68.
FRA:07X's Quick Ratio is ranked worse than 76.63% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:07X: 1.27
Annovis Bio (FRA:07X) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Annovis Bio Quick Ratio Related Terms
Annovis Bio Quick Ratio Historical Data
* Premium members only.
The historical data trend for Annovis Bio's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:07X vs HYFT, EXOZ, ACRV: Quick Ratio Comparison
For the Biotechnology subindustry, Annovis Bio's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annovis Bio Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annovis Bio's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Annovis Bio's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Annovis Bio's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annovis Bio (FRA:07X) has a Quick Ratio of 1.27 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Annovis Bio and its competitors. This is 73% below median its historical median of 4.68. Over the past decade, Annovis Bio's Quick Ratio has ranged from 0.09 to 55.99. According to the industry distribution chart, Annovis Bio ranks #1082 out of 1412 companies in the Biotechnology industry, placing it in the top 76.6%.
Is Annovis Bio's Quick Ratio too high?
Annovis Bio's current Quick Ratio of 1.27 is 73% below median its 10-year median of 4.68. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 55.99. The Biotechnology industry median Quick Ratio is 3.60. Annovis Bio's value of 1.27 is 64.7% below this industry median. Based on the distribution chart, Annovis Bio ranks #1082 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annovis Bio has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Annovis Bio's Quick Ratio compare to HYFT and EXOZ?
According to the Biotechnology industry distribution chart, Annovis Bio ranks #1082 out of 1412 companies for Quick Ratio. This places Annovis Bio in the lower half of its industry. The industry median Quick Ratio is 3.60. Annovis Bio's value of 1.27 is 64.7% below this benchmark. Historically, Annovis Bio's own Quick Ratio has ranged from 0.09 to 55.99 over the past decade. While the company's 10-year median is 4.68 vs. the industry median of 3.60, Annovis Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Annovis Bio's current Quick Ratio of 1.27 is 64.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Annovis Bio and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annovis Bio's current Quick Ratio is 1.27, which is 73% below median its own 10-year median of 4.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annovis Bio stock overvalued right now?
Annovis Bio (FRA:07X) has a current Quick Ratio of 1.27. The current Quick Ratio is 1.27, which is 73% below median its 10-year median of 4.68 and 64.7% below the Biotechnology industry median of 3.60. Annovis Bio's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Annovis Bio (FRA:07X), the current Quick Ratio is 1.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
38GF Score
Get the complete analysis for FRA:07X
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:07X has been successfully added to your 
